Genova Biotech

Genova Biotech is a biopharmaceutical company headquartered in Hangzhou, China, focused on the development and manufacturing of high-quality biologics. The company specializes in biosimilars and innovative monoclonal antibodies targeting autoimmune diseases, oncology, and ophthalmology. Its lead product, an infliximab biosimilar, has received regulatory approval in China, marking the company's transition to a commercial-stage entity. Genova Biotech operates a large-scale GMP-compliant manufacturing facility equipped with advanced mammalian cell culture technology. In addition to its biosimilar portfolio, the company is advancing a pipeline of next-generation therapies, including bispecific antibodies for retinal diseases. The firm aims to expand its global footprint through strategic partnerships and international clinical trials.